Triumvira Immunologics completes extension of Series A financing

On March 17, 2022, Triumvira Immunologics (“Triumvira”) announced the completion of an extension of its Series A financing, bringing the total round to approximately US$100 million. The Series A extension featured new investors, including significant participation from B Capital Group, along with ATEM Capital, the Myeloma Investment Fund, the Multiple Myeloma Research Foundation’s venture philanthropy subsidiary, and others, joined by significant participation from existing investors, Leaps by Bayer, the impact investment unit of Bayer AG, and Northpond Ventures.

The proceeds of the financing will support the continued preclinical and clinical development of Triumvira’s T cell Antigen Coupler (TAC)-T cell therapy programs.

Further information can be found on Canada Newswire’s website.

Triumvira Immunologics is a clinical-stage company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors.